Altria Posts Higher Six-Month Revenue and Profit but a Softer Standalone Quarter in Interim Filing

Bottom line

Altria Group, Inc. reported Revenue from Contract with Customer, Excluding Assessed Tax of $6,111,000,000 USD for the three months ended June 30, 2026, higher than the prior-year figure of $6,102,000,000 USD for the three months ended June 30, 2025; the same revenue line was $11,539,000,000 USD for the six months ended June 30, 2026, higher than the prior-year comparative of $11,361,000,000 USD for the six months ended June 30, 2025. Operating Income (Loss) was $3,136,000,000 USD for the three months ended June 30, 2026, a profit that was lower than the prior-year quarter's profit of $3,230,000,000 USD for the three months ended June 30, 2025; the year-to-date line showed Operating Income (Loss) of $6,092,000,000 USD for the six months ended June 30, 2026, higher than the prior-year comparative of $5,018,000,000 USD for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent was $2,298,000,000 USD for the three months ended June 30, 2026, a profit that was lower than the prior-year quarter's profit of $2,378,000,000 USD for the three months ended June 30, 2025; the year-to-date line was a profit of $4,481,000,000 USD for the six months ended June 30, 2026, higher than the prior-year comparative of $3,455,000,000 USD for the six months ended June 30, 2025. Earnings Per Share, Diluted was $1.37 per diluted share USD/SHARES for the three months ended June 30, 2026; the year-to-date figure was $2.67 per diluted share USD/SHARES for the six months ended June 30, 2026, higher than the prior-year comparative of $2.04 per diluted share USD/SHARES for the six months ended June 30, 2025. The quarter result was a profit, the prior-year quarter was a profit, and the half-year figure was a profit compared with a profit in the prior-year period. The filing evidence does not attribute this change to any single cause.

- The interim filing is presented by Altria as the unaudited interim condensed consolidated financial statements of ALTRIA GROUP, INC. under 10-Q for the three months ended June 30, 2026 and the six months ended June 30, 2026, filed under accession 0000764180-26-000094 by registrant 0000764180 (ticker MO) covering the period referenced in period-ended-2026-06-30. - The subsidiaries through which Altria operates include Philip Morris USA Inc. and Middleton (machine-made large cigars), UST LLC and USSTC (moist smokeless tobacco), Helix Innovations LLC and Helix International (oral nicotine pouches), NJOY, LLC (e-vapor), AGDC (domestic sales and distribution) and ALCS (support services); substantially all revenue is generated from domestic customers. - In the cited note on contingencies, management discloses an ITC exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, which became effective in March (omitted), and treats that development as a triggering event for an interim impairment assessment tied to (i) lower projected volume and revenue due to NJOY ACE's removal from the U.S. market and (ii) higher projected costs associated with the commercialization of NJOY's future e-vapor product portfolio. The filing evidence does not attribute this change to any single cause.

- The interim disclosure ties a recognized interim impairment for the e-vapor reporting unit to the NJOY ACE exclusion order, alongside amortization disclosures for definite-lived intangible assets that are referenced in Note 2 and to the goodwill and indefinite-lived intangible asset review process referenced in Note 14. - The benefit-plan disclosure context is captured in Note 6, the financial-instruments disclosure context in Note 5 and Level 1, and the exit-and-implementation-costs context in Note 3 and Level 3. Restricted-shares disclosure context appears in Level 2 and the cash, cash equivalents and restricted cash context in Note 13. Stockholders' equity disclosure context appears in Note 1 and Note 12, and investments in equity securities context in Note 4.

- The filing evidence does not contain a peer or industry comparison. The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for these dimensions. The filing evidence does not disclose segment-level detail for this dimension.

- The filing identifies reporting items outside the financial statements, including legal proceedings, risk factors, unregistered sales of equity securities and use of proceeds, other information, quantitative and qualitative disclosures about market risk, controls and procedures, exhibits and signatures. These appear in Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5 and Item 6.

Financial performance

- Reported facts: For the three-month reporting period, ALTRIA GROUP, INC. recorded Net Income (Loss) Attributable to Parent of $2,298,000,000 USD, below the prior-year comparative of $2,378,000,000 USD. Operating Income (Loss) for the quarter was $3,136,000,000 USD, lower than the prior-year reading of $3,230,000,000 USD.

37 per diluted share USD/SHARES. Across the year-to-date window, Net Income (Loss) Attributable to Parent increased to $4,481,000,000 USD from $3,455,000,000 USD, with Operating Income (Loss) climbing to $6,092,000,000 USD from $5,018,000,000 USD and Revenue from Contract with Customer, Excluding Assessed Tax moving higher to $11,539,000,000 USD from $11,361,000,000 USD. 04 per diluted share USD/SHARES in the prior year.

The figures are sourced from the 10-Q filed for period-ended-2026-06-30 under accession 0000764180-26-000094. S. GAAP, with management stating that all adjustments necessary for a fair interim presentation have been reflected and that interim results are not necessarily indicative of full-year outcomes.

The filing references the recent adoption of an Accounting Standards Update providing a practical expedient for calculating expected credit losses on current accounts receivable and contract assets, and describes the amortization period for definite-lived intangible assets as a weighted-average of roughly the cited span of years, dominated by intellectual property and certain cigarette trademarks. Pre-tax amortization expense is disclosed separately for the six-month and three-month periods. Goodwill and indefinite-lived intangible assets are subject to an annual review as of the cited calendar date, with interim assessment triggered by changing circumstances.

S. market. A facilities consolidation plan for USSTC's manufacturing operations and the multi-phase Optimize & Accelerate initiative are described, with employee separation and asset-related charges flagged.

- Analyst inference: On a year-over-year basis, the half-year window shows profit building on profit, with revenue, operating income, net income attributable to parent, and diluted earnings per share all higher than the prior year, while the standalone quarter shows revenue higher year over year but operating income and net income attributable to parent lower than the prior year, indicating that the full-year momentum is being carried by the earlier portion of the period. This mixed pattern across the two windows is consistent with the segment-level and product-level context surrounding the NJOY ACE disruption discussed in management's commentary.

- Counter-evidence: The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension. so the divergence between quarterly softness and half-year strength cannot be cross-checked against outside benchmarks.

- Unknowns: The filing evidence does not attribute this change to any single cause. Quarter-over-quarter sequencing of revenue and profit components within the second quarter is not enumerated here, and the filing references several notes, including the cited note on investments, financial instruments, benefit plans, exit and implementation costs, and additional financial statement information, that bear on cash flow and balance-sheet baselines but are not the subject of this section.

Operating drivers and segments

- Altria's principal revenue-generating subsidiaries remain Philip Morris USA (combustible cigarettes), Middleton (machine-made large cigars), UST/USSTC (moist smokeless tobacco), Helix/Helix International (oral nicotine pouches) and NJOY (e-vapor), with AGDC providing domestic sales and distribution and ALCS providing internal support services, all operating primarily in the United States. - Reported revenue from contracts with customers was $6,111,000,000 USD for the three-month period the three months ended June 30, 2026, compared with $6,102,000,000 USD for the three months ended June 30, 2025, a higher top-line on a quarter-over-prior-year basis.

- Reported revenue for the six-month year-to-date period the six months ended June 30, 2026 was $11,539,000,000 USD, higher than $11,361,000,000 USD for the six months ended June 30, 2025. - Reported operating income was $3,136,000,000 USD for the three months ended June 30, 2026, lower than $3,230,000,000 USD for the three months ended June 30, 2025 — a quarter-over-prior-year decline in operating profit even though revenue moved in the opposite direction. - Reported operating income for the six months ended June 30, 2026 was $6,092,000,000 USD, higher than $5,018,000,000 USD for the six months ended June 30, 2025, so the year-to-date operating result improved despite the quarterly reversal.

S. market following the ITC exclusion order discussed in Item 1 and the contingencies note, with intangible amortization policy disclosed under Note 2; segment-level revenue and operating margin splits beyond this narrative are not separately broken out in the cited interim package. - Management frames the interim presentation as GAAP-conformed, unaudited and consistent with prior practice, with the cited ASU adoption and continuing-amortization disclosures described in Note 14 and Note 13.

- The principal narrative driver is the NJOY ACE exclusion order, which management describes as the triggering event behind an interim e-vapor goodwill impairment tied to lower projected volume and higher projected commercialization costs. - Management also discusses continuing exit and implementation activities and benefit-plan accounting under Note 3 and Note 6, alongside investment holdings measured using Level 1 inputs under Note 5. - Independent readers can compare Altria's interim disclosure pattern with peer interim packages such as Goldman Sachs Group Inc Posts Higher Net Income and Diluted Earnings Per Share in Interim Filing on Both a Quarter-Over-Prior-Year and Year-to-Date Basis and Hartford Insurance Group Posts Higher Net Income, Diluted EPS, and Revenue on Both Quarter and Year-to-Date Bases in Interim Filing to gauge how a tobacco issuer's quarterly operating-profit dip against higher revenue stacks up against other interim reporters.

The filing evidence does not attribute this change to any single cause. The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison.

Cash flow and capital

Altria's liquidity position at the balance sheet date of the balance sheet date of June 30, 2026 rests on a cash balance of $2,367,000,000 against long-term debt, excluding current maturities, of $22,893,000,000. The relative weight of those two balances frames every financing decision discussed below, and the trade-off between servicing that debt and returning cash to shareholders is the through-line of this section.

Operating cash generation is the engine that funds both the dividend and the buyback. For the six-month year-to-date period the six months ended June 30, 2026, net cash provided by operating activities was $3,043,000,000, which is higher than the $2,925,000,000 recorded in the prior-year comparative period the six months ended June 30, 2025. Operating cash flow therefore expanded year over year, providing the headline cash that management then allocates across investing, financing and capital-return activities.

On the investing side, the company used cash during both periods. Net cash used in investing activities was -$166,000,000 for the current six-month period the six months ended June 30, 2026, which is a decrease from the -$79,000,000 recorded for the prior-year comparative period the six months ended June 30, 2025. Within that envelope, payments to acquire property, plant and equipment were $150,000,000, higher than the $70,000,000 of the prior-year comparative period the six months ended June 30, 2025. The higher capex reading is consistent with the capital projects flagged in the filing narrative, including the USSTC Facilities Consolidation announced in May (omitted), which is expected to generate employee-separation and other cash charges alongside non-cash asset write-downs, and the multi-phase Optimize & Accelerate initiative, whose charges are described as cash expenditures for severance, new technology and business advisory services.

Financing activities were a net use of cash in both periods, with the outflow widening. Net cash used in financing activities was -$4,988,000,000 for the current six-month period the six months ended June 30, 2026, a decrease from the -$4,693,000,000 recorded for the prior-year comparative period the six months ended June 30, 2025. The two principal uses of cash within that financing bucket moved in opposite directions. Payments for the repurchase of common stock fell to $335,000,000 from $600,000,000 in the prior-year comparative period the six months ended June 30, 2025, so buyback spending contracted even as operating cash flow expanded. Payments of ordinary dividends on common stock, by contrast, rose to $3,556,000,000 from $3,454,000,000 in the prior-year comparative period the six months ended June 30, 2025, leaving the dividend as the larger and rising call on operating cash.

Read together, the year-to-date picture is one of stronger operating cash generation funding higher capex and higher dividends, with the gap absorbed by a larger net financing outflow — that is, a smaller buyback rather than a heavier debt build. The filing narrative also discloses contingent cash demands tied to the e-vapor reporting unit: a triggering event in the period ended March (omitted) led to an interim impairment assessment of e-vapor goodwill and indefinite-lived intangible assets, and pre-tax exit and implementation charges are tied to the Optimize & Accelerate initiative. The fair-value inputs for those impairment analyses are categorized within Level 3 of the fair value hierarchy. Equity-method investments in ABI and Cronos are reported on a one-quarter lag, and the fair value of the ABI investment is split between Level 1 for ordinary shares and Level 2 for the Restricted Shares, with the Restricted Shares convertible one-for-one into ABI ordinary shares. The filing also notes that the company may designate Euro-denominated unsecured long-term notes and foreign currency contracts as net investment hedges of its ABI investment, tying a portion of the long-term debt balance to foreign-currency risk management.

Peer and historical context

Altria's period-ended-2026-06-30 10-Q filing under accession 0000764180-26-000094 offers a clear year-over-year view against the company's own prior-year results but provides no benchmark against any peer issuer. Revenue from Contract with Customer, Excluding Assessed Tax is higher in both reporting windows than in the prior year: the three-month figure of $6,111,000,000 USD sits above the prior-year quarter's $6,102,000,000 USD, and the six-month figure of $11,539,000,000 USD sits above the prior-year half's $11,361,000,000 USD. Operating Income (Loss), however, splits in the opposite direction across the two windows — the three-month operating profit of $3,136,000,000 USD is lower than the prior-year quarter's $3,230,000,000 USD, while the six-month operating profit of $6,092,000,000 USD is higher than the prior-year half's $5,018,000,000 USD. Net Income (Loss) Attributable to Parent tracks the same split: the three-month result of $2,298,000,000 USD is lower than the prior-year quarter's $2,378,000,000 USD, whereas the six-month result of $4,481,000,000 USD is higher than the prior-year half's $3,455,000,000 USD, with the quarter-to-prior-year transition remaining profit to profit. Operating cash generation strengthens across the half-year, with Net Cash Provided by (Used in) Operating Activities of $3,043,000,000 USD exceeding $2,925,000,000 USD. The filing evidence does not attribute this change to any single cause.

- Read against a recent interim reading from a different sector, such as Hartford Insurance Group Posts Higher Net Income, Diluted EPS, and Revenue on Both Quarter and Year-to-Date Bases in Interim Filing, Altria's combination of higher revenue alongside lower quarter-on-quarter net income stands out as a divergent pattern; the filing does not reconcile it. - The Optimize & Accelerate initiative, the USSTC Facilities Consolidation discussed under Note 3, and the contingent-payment liability tied to the NJOY Transaction classified in Level 3 of the fair value hierarchy are flagged in the source narrative as ongoing cost items, yet the filing does not tie any of them directly to the quarter-over-quarter operating-income step-down. - On the half-year basis, Earnings Per Share, Diluted is higher than the prior-year half, mirroring the net-income direction, with the authorized transition remaining profit to profit. - Capital-return activity for the half-year shows Payments of Ordinary Dividends, Common Stock higher than the prior-year half, Payments for Repurchase of Common Stock lower than the prior-year half, and Payments to Acquire Property, Plant, and Equipment higher than the prior-year half, indicating continued reinvestment alongside shareholder returns.

The filing evidence contains no peer or industry comparison.

Scenario analysis

Reading the headline figures in the cited note together suggests a stable, mid-case path: revenue from contracts with customers of $11,539,000,000 for the six-month period of the six months ended June 30, 2026 sits above the prior-year comparative of $11,361,000,000, and the quarterly topline of $6,111,000,000 for the three months ended June 30, 2026 is also higher than $6,102,000,000. Year-to-date net income attributable to the parent of $4,481,000,000 extends the prior-period profit of $3,455,000,000, holding the franchise in the profit-to-profit transition that the cited evidence already confirms. The filing evidence does not attribute this change to any single cause. Quarterly net income of $2,298,000,000 softens against $2,378,000,000, so the base case blends a softer single quarter with a firmer half-year trajectory.

Under the more constructive read, the half-year revenue lift of $6,111,000,000 over $6,102,000,000 combined with the six-month topline gain of $11,539,000,000 versus $11,361,000,000 points to volume and pricing holding up through the period of the three months ended June 30, 2026. Profitability would broaden if the half-year net income of $4,481,000,000 carried through the back half of the year, with cash returns to shareholders under the Optimize & Accelerate cost program acting as a tailwind alongside the prior spending on share repurchases and ordinary dividends. The Cronos and ABI equity-method exposures, foreign-currency net investment hedges, NJOY menthol and other pod authorizations, and contingent-payment settlement premiums all sit in management's hands to shape the upside, but The filing evidence does not attribute this change to any single cause. for how those levers flow into the headline. Peer cross-checks for benchmarking such as Hartford Insurance Group Posts Higher Net Income, Diluted EPS, and Revenue on Both Quarter and Year-to-Date Bases in Interim Filing read in the same broad direction for insurers but do not translate to tobacco results.

The cautious read leans on the quarter-on-quarter swing in net income, with $2,298,000,000 below $2,378,000,000 even while the year-to-date line of $4,481,000,000 still exceeds $3,455,000,000. If the favorable half-year revenue comparisons of $11,539,000,000 against $11,361,000,000 and $6,111,000,000 against $6,102,000,000 fade as the Optimize & Accelerate severance, implementation, and advisory cash costs continue to weigh, the operating profit transition could compress. The filing evidence does not attribute this change to any single cause. for the size of any margin compression. Equity-method results from ABI and Cronos, foreign-currency translation, fair-value movements across the lower-tier hierarchy, and contingent-payment remeasurement tied to NJOY authorization timing all introduce additional variance into the bottom line. The filing evidence contains no peer or industry comparison. for benchmarking the downside against other tobacco or consumer-staples names, leaving the risk frame anchored entirely in ALTRIA GROUP, INC.'s own filings under 10-Q.

Risks and what to watch

- Reported facts: For the three-month reporting period, the company recorded net income attributable to parent of $2,298,000,000 USD (a profit) and revenue from contracts with customers, excluding assessed tax, of $6,111,000,000 USD. For the six-month year-to-date period, net income attributable to parent was $4,481,000,000 USD and revenue was $11,539,000,000 USD. The prior-year comparatives were $2,378,000,000 USD and $6,102,000,000 USD for the quarter, and $3,455,000,000 USD and $11,361,000,000 USD for the year-to-date period.

- Management explanations: The narrative around the NJOY acquisition describes FDA authorizations for NJOY ACE menthol, blueberry, and watermelon pod products, with contingent payments recognized at estimated fair value at the acquisition date and subsequent changes flowed through earnings. The liability for those contingent payments sits in Level 3 of the fair value hierarchy, indicating judgments about regulatory outcomes that remain unresolved. Investments in ABI and Cronos are carried at fair value using quoted market prices in Level 1 (ordinary and common shares) and Level 2 (Restricted Shares).

A one-quarter reporting lag is applied to Cronos results because they are not available in time for the concurrent period. Foreign currency exposure on the Euro-denominated ABI investment is managed through net investment hedges using Euro denominated unsecured long-term notes and foreign currency contracts. - Analyst inference: The fair-value mechanics signal meaningful exposure to quoted equity prices for ABI and Cronos, so future mark-to-market swings will flow into earnings even when the underlying operating performance is unchanged.

The contingent-payment liability classification in Level 3 highlights that management's estimate depends on a regulatory probability judgment, which can shift as FDA actions progress. The Cronos reporting lag means investors see Cronos results with a delay, complicating quarter-on-quarter comparisons. - Counter-evidence: No offsetting factor was disclosed that would moderate the regulatory-contingency exposure on the NJOY contingent payment or the ABI/Cronos mark-to-market sensitivity.

The filing does not present hedging effectiveness ratios or sensitivity analyses that would let a reader gauge the size of those exposures in dollar terms. - Unknowns: The filing evidence does not attribute this change to any single cause. Segment-level performance detail that would clarify which businesses drove the quarter-over-quarter movements is not disclosed at this level.

The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison. S.

dollar movement on the Euro denominated unsecured long-term notes; and the catch-up contribution from Cronos under the one-quarter lag. Readers comparing interim tobacco filings can also cross-check patterns in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing for context on how peers disclose year-to-date movements.